Correlation Between Viridian Therapeutics and Vaxcyte

Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Vaxcyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Vaxcyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viridian Therapeutics and Vaxcyte, you can compare the effects of market volatilities on Viridian Therapeutics and Vaxcyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Vaxcyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Vaxcyte.

Diversification Opportunities for Viridian Therapeutics and Vaxcyte

0.41

Correlation Coefficient

Viridian Therapeutics  Vaxcyte

Very weak diversification

The 3 months correlation between Viridian and Vaxcyte is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Vaxcyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaxcyte and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Vaxcyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaxcyte has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Vaxcyte go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Vaxcyte

Given the investment horizon of 90 days Viridian Therapeutics is expected to generate 2.46 times more return on investment than Vaxcyte. However, Viridian Therapeutics is 2.46 times more volatile than Vaxcyte. It trades about 0.15 of its potential returns per unit of risk. Vaxcyte is currently generating about -0.1 per unit of risk. If you would invest  1,447  in Viridian Therapeutics on August 31, 2024 and sell it today you would earn a total of  740.00  from holding Viridian Therapeutics or generate 51.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Viridian Therapeutics  vs.  Vaxcyte

Viridian Therapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting fundamental indicators, Viridian Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Vaxcyte

Risk-Adjusted Performance

0 of 100

Modest

Over the last 90 days Vaxcyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Viridian Therapeutics and Vaxcyte

The main advantage of trading using opposite Viridian Therapeutics and Vaxcyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Vaxcyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcyte will offset losses from the drop in Vaxcyte's long position.

The idea behind Viridian Therapeutics and Vaxcyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.